⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4707868 | 0.79 | — | — | |
| SCHEMBL17117074 | 0.76 | — | — | |
| SCHEMBL2020184 | 0.74 | — | — | |
| SCHEMBL30636750 | 0.73 | — | — | |
| SCHEMBL28773909 | 0.73 | — | — | |
| SCHEMBL9158543 | 0.69 | — | — | |
| SCHEMBL7781683 | 0.69 | TSHR (0.30) | — | |
| SCHEMBL29155445 | 0.67 | — | — | |
| SCHEMBL9299517 | 0.67 | — | — | |
| SCHEMBL15209513 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326760-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4438117-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-10-02 | — | — | EP | disclosed |
| EP-3658557-B1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-05 | — | — | EP | disclosed |
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20220356184-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-10 | — | — | US | disclosed |
| CN-113166153-A | Fused pyrazine derivatives as A2A/A2B inhibitors | 因赛特公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| EP-3658557-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| CN-101472896-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | CN | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2035389-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2035388-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007148061-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148062-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
| EP-1831177-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067443-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |